Pradaxa Bleeding Risk Gets Deeper FDA Scrutiny In Mini-Sentinel Project
This article was originally published in The Pink Sheet Daily
Executive Summary
A 2012 Sentinel study didn’t find any problems, but FDA wants a closer look now that the dataset has grown.
You may also be interested in...
Pradaxa Medicare Study: Observing a Slow Attitude Change at FDA on Observational Studies
CDER Deputy Director Bob Temple is a confirmed skeptic of the value of observational trial data to FDA’s regulatory decisions. A recent Medicare study on the bleeding risks associated with Boehringer-Ingelheim’s Pradaxa, however, confirmed an earlier position on the drug by FDA and meets with Temple’s approbation.
Boehringer Avoids Pradaxa Trial, Board Chair Deposition With $650 Mil. Settlement
Settlement expected to resolve approximately 4,000 Pradaxa personal injury claims.
Pradaxa Increases GI Bleeding But Not Heart Attack Risk, Medicare Data Show
Higher incidence of gastrointestinal bleeding among the Medicare population contrasts with findings from an earlier Mini-Sentinel study of dabigatran and bleeding, but FDA said the disparity in results may reflect the age differences in the populations examined.